← 홈

Antibody

1,230개 · ADC 1032 · Antibody 4683 · CGT 2713 · 다음 갱신 D-7 · 마지막 7월 21일

인기최근 업데이트큐레이션임상 많은갱신 필요ORR최신Phase 3FDA승인프로그램 1,230개
AntibodystaleGlostrup University Hospital, C…Approved

etanercept or adalimumab (Discontinuation of TNF-alpha inhibitor and re-starting it if flare-up in disease activity, Discontinuation of TNF-alpha inhibitor and re-starting it if flare-up in disease activity (etanercept or adalimumab))

SPONDYLOARTHRITIS · SPONDYLOARTHRITIS

#SPONDYLOARTHRITIS#Antibody#Approved#항체#면역항체+2
임상시험 1상태 DISCONTINUED
AntibodystaleSanofiPhase 2

Docetaxel (Docetaxel, Docetaxel (T) + bevacizumab)

Breast Cancer · Breast Cancer

#BreastCancer#Antibody#Phase2#항체#면역항체+2
임상시험 1상태 ACTIVE
AntibodystaleHenan Cancer HospitalPhase 3

trastuzumab (Herceptin, Docetaxel+ carboplatin+ trastuzumab + patuzumab)

Breast Cancer,HER2-positive · HER2

#HER2#Antibody#Phase3#항체#면역항체+4
임상시험 1상태 RECRUITING
AntibodystaleRochePhase 2

Docetaxel, Capecitabine, Cisplatin, Bevacizumab (Docetaxel, Capecitabine, Cisplatin, Bevacizumab)

Advanced Gastric Cancer · Advanced Gastric Cancer

#AdvancedGastricCancer#Antibody#Phase2#항체#면역항체+2
임상시험 1상태 ACTIVE
AntibodystaleCancer Trials IrelandPhase 2

trastuzumab (Herceptin, Docetaxel, Carboplatin and Trastuzumab)

Breast Cancer · Breast Cancer

#BreastCancer#Antibody#Phase2#항체#면역항체+2
임상시험 1상태 ACTIVE
AntibodystaleCancer Trials IrelandPhase 2

trastuzumab (Herceptin, Docetaxel, Carboplatin, Trastuzumab and Lapatinib)

Breast Cancer · Breast Cancer

#BreastCancer#Antibody#Phase2#항체#면역항체+2
임상시험 1상태 ACTIVE
AntibodystaleHong Kong Nasopharyngeal Cancer…Phase 2

Docetaxel, Cisplatin, 5-FU and Cetuximab (Docetaxel, Cisplatin, 5-FU and Cetuximab)

Nasopharyngeal Carcinoma · Nasopharyngeal Carcinoma

#NasopharyngealCarcinoma#Antibody#Phase2#항체#면역항체+2
임상시험 1상태 ACTIVE
AntibodystaleMemorial Sloan Kettering Cancer…Phase 2

Docetaxel, Cisplatin, Fluorouracil, Bevacizumab, Leucovorin (Docetaxel, Cisplatin, Fluorouracil, Bevacizumab, Leucovorin)

Stomach Neoplasms; Esophageal Neoplasms · Stomach Neoplasms

#StomachNeoplasms#Antibody#Phase2#항체#면역항체+3
효능 ORR 85%임상시험 1상태 ACTIVE
AntibodystaleAuxilio Mutuo Cancer CenterPhase 2

trastuzumab (Herceptin, Docetaxel, Epirubicin, Cyclophosphamide/Navelbine, Capecitabine, Trastuzumab, Bevacizumab)

Infiltrating Duct and Lobular Carcinoma In Situ; Invasive Lobular Breast Carcinoma · Infiltrating Duct and Lobular Carcinoma

#InfiltratingDuctandLobularCarcin#Antibody#Phase2#항체#면역항체+3
임상시험 1상태 ACTIVE
AntibodystaleMemorial Sloan Kettering Cancer…Phase 2

trastuzumab (Herceptin, Docetaxel, Leukvorin, Flurouracil, Cisplatin, Trastuzumab)

Gastroesophageal Junction Adenocarcinoma; Gastric Cancer · Gastroesophageal Junction Adenocarcinoma

#GastroesophagealJunctionAdenocar#Antibody#Phase2#항체#면역항체+3
임상시험 1상태 ACTIVE
AntibodystaleThe Netherlands Cancer InstitutePhase 2

Docetaxel, Oxaliplatin, Capecitabin, Bevacizumab (Docetaxel, Oxaliplatin, Capecitabin, Bevacizumab)

Metastatic Gastric Cancer; Adenocarcinoma of the Gastro-oesophageal Junction · Metastatic Gastric Cancer

#MetastaticGastricCancer#Antibody#Phase2#항체#면역항체+3
임상시험 1상태 ACTIVE
AntibodystaleThe Netherlands Cancer InstitutePhase 2

trastuzumab (Herceptin, Docetaxel, Oxaliplatin, Capecitabin, Bevacizumab, Trastuzumab)

Metastatic Gastric Cancer; Adenocarcinoma of the Gastro-oesophageal Junction · Metastatic Gastric Cancer

#MetastaticGastricCancer#Antibody#Phase2#항체#면역항체+3
임상시험 1상태 ACTIVE
AntibodystaleAstraZenecaPhase 2

durvalumab (Imfinzi, Docetaxel, Oxaliplatin, S-1 and Durvalumab)

Resectable Gastric or Gastroesophageal Junction Adenocarcinoma · Resectable Gastric or Gastroesophageal J

#ResectableGastricorGastroesophag#Antibody#Phase2#항체#면역항체+2
임상시험 1상태 ACTIVE
AntibodystaleSanofiPhase 2

trastuzumab (Herceptin, TCH, Docetaxel, carboplatin, trastuzumab, Docetaxel, carboplatin, trastuzumab (TCH) + bevacizumab)

Breast Cancer · Breast Cancer

#BreastCancer#Antibody#Phase2#항체#면역항체+2
임상시험 1상태 ACTIVE
AntibodystaleSanofiPhase 2

Docetaxel, doxorubicin, cyclophosphamide (TAC, Docetaxel, doxorubicin, cyclophosphamide, Docetaxel, doxorubicin, cyclophosphamide (TAC) + bevacizumab)

Breast Cancer · Breast Cancer

#BreastCancer#Antibody#Phase2#항체#면역항체+2
임상시험 1상태 ACTIVE
AntibodystaleMerrimack PharmaceuticalsPhase 1

trastuzumab (Herceptin, Docetaxel, trastuzumab and MM-111)

HER-2 Gene Amplification · HER-2 Gene Amplification

#HER-2GeneAmplification#Antibody#Phase1#항체#면역항체+2
임상시험 1상태 ACTIVE
AntibodystaleRochePhase 2

Docetaxel/Carboplatin/Bevacizumab/Erlotinib (Docetaxel/Carboplatin/Bevacizumab/Erlotinib)

Non-Small Cell Lung Cancer · Non-Small Cell Lung Cancer

#Non-SmallCellLungCancer#Antibody#Phase2#항체#면역항체+2
임상시험 1상태 ACTIVE
AntibodystaleGilead SciencesPhase 2

DOM (Domvanalimab, Domvanalimab (DOM))

Lung Cancer; Advanced or Metastatic Non-Small-Cell Lung Cancer · Lung Cancer

#LungCancer#Antibody#Phase2#항체#면역항체+3
임상시험 1상태 RECRUITING
AntibodystaleTesaro, Inc.Phase 3

TSR-042 (Dostarlimab, Dostarlimab (TSR-042))

Ovarian Neoplasms; Ovarian, Fallopian Tube and Primary Peritoneal Carcinoma · Ovarian Neoplasms

#OvarianNeoplasms#Antibody#Phase3#항체#면역항체+4
효능 ORR 88%임상시험 1상태 RECRUITING
AntibodystaleUniversity of LeicesterPhase 2

Dostarlimab and Niraparib (Dostarlimab and Niraparib)

Mesothelioma, Malignant · Mesothelioma, Malignant

#MesotheliomaMalignant#Antibody#Phase2#항체#면역항체+4
임상시험 1상태 ACTIVE

28 / 62 페이지

← 이전다음 →